{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:38:25Z","timestamp":1792813105028,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018748","name":"argenx nv","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jns.2024.123264","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T04:21:35Z","timestamp":1728015695000},"page":"123264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Post-hoc analyses from the ADAPT clinical study demonstrate aggregate sustained benefit of Efgartigimod in generalized myasthenia gravis"],"prefix":"10.1016","volume":"466","author":[{"given":"Sarah","family":"Dewilde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia Z.","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Gelinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Brauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Mantegazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"James F.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2024.123264_bb0005","doi-asserted-by":"crossref","unstructured":"Phillips LH. The epidemiology of myasthenia gravis. Semin. Neurol. Mar 2004;24(1):17\u201320. doi:https:\/\/doi.org\/10.1055\/s-2004-829593.","DOI":"10.1055\/s-2004-829593"},{"key":"10.1016\/j.jns.2024.123264_bb0010","author":"European Medicine Agency"},{"key":"10.1016\/j.jns.2024.123264_bb0015","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000212371","article-title":"Myasthenia gravis with anti-acetylcholine receptor antibodies","volume":"26","author":"Meriggioli","year":"2009","journal-title":"Front. Neurol. Neurosci."},{"key":"10.1016\/j.jns.2024.123264_bb0020","author":"Stroke NIoNDa"},{"key":"10.1016\/j.jns.2024.123264_bb0025","doi-asserted-by":"crossref","first-page":"1247931","DOI":"10.3389\/fpubh.2023.1247931","article-title":"The economic burden of individuals living with generalized myasthenia gravis and facing social determinants of health challenges","volume":"11","author":"Hughes","year":"2023","journal-title":"Front. Public Health"},{"issue":"4","key":"10.1016\/j.jns.2024.123264_bb0030","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2024.123264_bb0035","doi-asserted-by":"crossref","unstructured":"Howard JF, Jr., Vissing J, Gilhus NE, et al. Zilucoplan: an investigational complement C5 inhibitor for the treatment of acetylcholine receptor autoantibody-positive generalized myasthenia gravis. Expert Opin. Investig. Drugs May 2021;30(5):483\u2013493. doi:https:\/\/doi.org\/10.1080\/13543784.2021.1897567.","DOI":"10.1080\/13543784.2021.1897567"},{"key":"10.1016\/j.jns.2024.123264_bb0040","author":"Medicine NUNLo"},{"key":"10.1016\/j.jns.2024.123264_bb0045","author":"Medicine NUNLo"},{"key":"10.1016\/j.jns.2024.123264_bb0050","author":"ClinicalTrials.Gov NUNLoM"},{"issue":"7","key":"10.1016\/j.jns.2024.123264_bb0055","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2024.123264_bb0060","doi-asserted-by":"crossref","first-page":"1284444","DOI":"10.3389\/fneur.2023.1284444","article-title":"Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis","volume":"14","author":"Howard","year":"2024","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jns.2024.123264_bb0065","first-page":"841","article-title":"Reliability testing of the quantitative myasthenia gravis score","author":"Barohn RJ, McIntire DH, Herbelin L, Wolfe GI, Nations S, WW. B","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"7","key":"10.1016\/j.jns.2024.123264_bb0070","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2024.123264_bb0075","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1749-6632.2012.06817.x","article-title":"The myasthenia gravis-specific activities of daily living profile","volume":"1274","author":"Muppidi","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"5","key":"10.1016\/j.jns.2024.123264_bb0080","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/mus.23988","article-title":"Minimal clinically important difference in myasthenia gravis: outcomes from a randomized trial","volume":"49","author":"Katzberg","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2024.123264_bb0085","series-title":"The GLIMMIX Procedure. SAS\/STAT\u00ae 131 User's Guide","author":"SAS Institute Inc","year":"2013"},{"key":"10.1016\/j.jns.2024.123264_bb0090","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420911784","article-title":"Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study","volume":"13","author":"Jacob","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.jns.2024.123264_bb0095","series-title":"No change in risk of infection among NMOSD and refractory gMG patients treated with eculizumab: Findings from two phase 3 studies and their extensions","first-page":"381","author":"Mantegazza","year":"2020"},{"key":"10.1016\/j.jns.2024.123264_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.556104","article-title":"Concomitant immunosuppressive therapy use in Eculizumab-treated adults with generalized myasthenia gravis during the REGAIN open-label extension study","volume":"11","author":"Nowak","year":"2020","journal-title":"Front. Neurol."},{"issue":"5","key":"10.1016\/j.jns.2024.123264_bb0105","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","article-title":"Clinical effects of the self-administered subcutaneous complement inhibitor Zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled, Multicenter Clinical Trial","volume":"77","author":"Howard","year":"2020","journal-title":"JAMA Neurol."},{"issue":"6","key":"10.1016\/j.jns.2024.123264_bb0110","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.jns.2024.123264_bb0115","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2024.123264_bb0120","series-title":"Presented at: 76th Annual Meeting of the American Academy of Neurology","article-title":"Fixed-Cycle and Continuous Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Study Design of ADAPT NXT","author":"Bril","year":"2024"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24004003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24004003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T05:06:25Z","timestamp":1741064785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X24004003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":24,"alternative-id":["S0022510X24004003"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2024.123264","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-hoc analyses from the ADAPT clinical study demonstrate aggregate sustained benefit of Efgartigimod in generalized myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2024.123264","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"123264"}}